Activating signaling mutations are common in acute leukemia with KMT2A (previously MLL) rearrangements (KMT2A-R). These mutations are often subclonal and their biological impact remains unclear. Using a retroviral acute myeloid mouse leukemia model, we demonstrate that FLT3 ITD , FLT3 N676K , and NRAS G12D accelerate KMT2A-MLLT3 leukemia onset. Further, also subclonal FLT3 N676K mutations accelerate disease, possibly by providing stimulatory factors. Herein, we show that one such factor, MIF, promotes survival of mouse KMT2A-MLLT3 leukemia initiating cells. We identify acquired de novo mutations in Braf, Cbl, Kras, and Ptpn11 in KMT2A-MLLT3 leukemia cells that favored clonal expansion. During clonal evolution, we observe serial genetic changes at the Kras G12D locus, consistent with a strong selective advantage of additional Kras G12D . KMT2A-MLLT3 leukemias with signaling mutations enforce Myc and Myb transcriptional modules. Our results provide new insight into the biology of KMT2A-R leukemia with subclonal signaling mutations and highlight the importance of activated signaling as a contributing driver.
G enetic rearrangements of the Histone-lysine N-methyltransferase 2A gene (KMT2A, previously MLL) is seen in approximately 10% of human acute leukemia 1 . However, in acute lymphoblastic leukemia (ALL) occurring in infants less than 1 year of age, a leukemia subtype with a particularly poor prognosis, close to 80% have KMT2A-rearrangements (KMT2A-R) [1] [2] [3] . We have previously shown that infant KMT2A-R ALL has a strikingly low number of mutations with an average of 2.2 non-silent single-nucleotide variants per case, and 1.3 in the dominant leukemia clone 4 . About half of these mutations occurred in kinase/phosphoinositide 3-kinase (PI3K)/RAS signaling pathways, suggesting that they are important cooperating events 4, 5 . Kinase/PI3K/RAS pathway mutations are also common in KMT2A-R ALL and acute myeloid leukemia (AML) arising in older children and adults [2] [3] [4] 6, 7 .
In infant KMT2A-R ALL, most of the mutations that deregulate protein components of signal transduction networks are subclonal, as indicated by their mutant allele frequencies (MAF) <0. 30 . In addition, some cases harbor multiple activating mutations at varying MAFs, suggesting the presence of multiple leukemic clones 4 . Further, analyses of paired diagnostic-relapse samples have shown that signaling mutations may be lost, maintained, or gained at relapse 4, 8, 9 . Thus, there is a delicate selection process that shapes clonal evolution during leukemia progression, treatment, and relapse. Mouse models have shown a potent genetic cooperativity between signaling mutations and KMT2A-Rs, with the most prominent pathophysiological combinatorial gain being acceleration of disease onset [10] [11] [12] [13] [14] [15] [16] [17] . However, none of these models have recapitulated the biology of subclonal activating mutations.
The mechanisms by which signaling mutations affect leukemogenesis, whether present at high or low MAF, and the biological processes controlling and shaping the intricate selection of evolving leukemic clones, remain poorly understood. To gain a better understanding of these processes, we studied the functional importance of constitutively activated FLT3-and RAS-signaling in KMT2A-mediated leukemogenesis in mouse. We focused our efforts on FLT3 ITD , FLT3 N676K , and NRAS G12D , as FLT3 and NRAS are the most common targets of mutations that deregulate signal transduction in AML, and studied clonal evolution of leukemia cells carrying subclonal activating mutations over time.
Herein, we show that also subclonal activating mutations, as demonstrated by FLT3 N676K , accelerate KMT2A-MLLT3 leukemia onset. Moreover, we identify acquired de novo activating mutations in known cancer-associated genes in KMT2A-MLLT3 leukemia cells that favored clonal expansion, indicating a strong 
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Fig. 1 FLT3-and RAS-signaling mutations accelerate AML onset. a Kaplan-Meier survival curves of mice transplanted with bone marrow (BM) cells cotransduced with KMT2A-MLLT3 and either FLT3 ITD , FLT3 N676K , or NRAS G12D (n = 7 for all groups), showing accelerated disease onset for mice receiving KMT2A-MLLT3 and either of the activating mutations (P = 0.0002 for KMT2A-MLLT3 + FLT3 ITD , P = 0.0002 for KMT2A-MLLT3 + FLT3 N676K , and P = 0.0004 for KMT2A-MLLT3 + NRAS G12D , as compared to KMT2A-MLLT3 + Empty-GFP. Mantel-Cox log-rank test). b Flow cytometric analysis of BM from sacrificed mice showed that a majority of cells were GFP + mCherry + in mice co-expressing KMT2A-MLLT3 and an activating mutation. c Hematoxylin-eosin stained sections from bone marrow, liver, and spleen (original magnification 200×, scale bar 0.1 mm, for bone marrow and 40×, scale bar 0.5 mm, for spleen and liver). The architecture of the spleen is effaced and the red pulp is expanded mainly due to expansion of immature myeloid cells. In the liver, periportal, perisinusoidal and intrasinusoidal extensive infiltrates of immature hematopoietic cells were noted. d Kaplan-Meier curves for secondary recipients transplanted with primary leukemic splenocytes showing that only KMT2A-MLLT3 + NRAS G12D sustained a significant difference in disease latency when compared to KMT2A-MLLT3 + Empty-GFP (P < 0.0001. Mantel-Cox log-rank test). ***P ≤ 0.001, ****P ≤ 0.0001; ns, not significant selective pressure for activated signaling as a cooperating event in KMT2A-R leukemogenesis.
Results

FLT3-and RAS-signaling mutations accelerate AML onset.
We here studied constitutively activated FLT3-and RAS-signaling in KMT2A-R leukemogenesis. First, we focused on the impact of FLT3 ITD , FLT3 N676K , or NRAS G12D when present as a dominant leukemia clone at disease manifestation. Mouse hematopoietic stem and progenitor cells (c-Kit + cells) were co-transduced with retroviral vectors expressing KMT2A-MLLT3-mCherry and FLT3 ITD -GFP, FLT3 N676K -GFP, NRAS G12D -GFP, or a GFP control vector (Empty-GFP) ( Supplementary Fig. 1a, b) . Expression of mutant NRAS and FLT3 in the mouse leukemia cell line Ba/F3 resulted in elevated phosphorylated p-AKT and p-ERK1/2, as well as p-STAT5 for FLT3 ITD (Supplementary Fig. 1c ). Transduced cells were transplanted unfractionated and at transplantation, only a minor fraction of cells co-expressed KMT2A-MLLT3 and NRAS G12D , FLT3 ITD , or FLT3 N676K (Supplementary Fig. 1d ). Despite this, all of them accelerated leukemia onset (median latency of 13, 23, 26 days, respectively, versus 50 days for KMT2A-MLLT3 alone; P = 0.0004, P = 0.0002, and P = 0.0002, respectively. Mantel-Cox log-rank test) (Fig. 1a) , consistent with a competitive growth advantage for these cells. In agreement with this, a majority of cells in the bone marrow (BM) contained both a signaling mutation and KMT2A-MLLT3 (Fig. 1b,  Supplementary Fig. 1e ), supporting a prominent genetic cooperativity between the KMT2A-R and activating FLT3 and RAS mutations, including the recently identified FLT3 N676K 4,18 . Mice displayed leukocytosis, splenomegaly, expression of CD11b and Gr-1 in BM cells, and a similar burden of leukemic granulocyte-macrophage-like-progenitors 10, 19 ( Supplementary  Fig. 1f-i and Supplementary Fig. 2a-c) . The BM, spleen, and liver showed infiltration of blasts and cytopenia, and peripheral blood (PB) an increase of blasts and progenitors (>20%) (Fig. 1c) . Thus, mice succumbed to AML 20 . Leukemias with an activating mutation showed presence of p-ERK1/2, and also p-STAT5 for those with FLT3 ITD . All leukemias displayed similar phosphorylation levels of P38 (Supplementary Fig. 3 ).
Leukemic cells isolated from the spleen of moribund mice gave rise to secondary malignancies identical to the primary disease in sublethally irradiated recipients, and with significantly reduced disease latency ( Fig. 1d and Supplementary Fig. 4a-d) . A continued enrichment for KMT2A-R leukemic cells carrying FLT3 ITD , FLT3 N676K , or NRAS G12D , was seen, consistent with a persistent competitive advantage for these cells ( Supplementary  Fig. 4e ). Disease latency of secondary KMT2A-MLLT3 recipients was similar to those with an activating mutation, suggesting that they had adapted a comparable leukemic phenotype to those with activating mutations.
Subclonal FLT3 N676K accelerates AML onset. In infant KMT2A-R ALL, a majority of the kinase/PI3K/RAS-pathway mutations are present in subclones 4, 5 accelerates AML onset. a Flow cytometric analysis on BM cells from primary KMT2A-MLLT3 + FLT3 N676K recipients revealed the presence of either a dominant clone (>50% GFP + mCherry + , n = 17), or a subclone (<50% GFP + mCherry + , n = 7) of KMT2A-MLLT3-mCherry + FLT3 N676K -GFP expressing cells. b Kaplan-Meier curves of mice transplanted with KMT2A-MLLT3 and FLT3 N676K (n = 24) or with Empty-GFP vector control (n = 21) showing accelerated disease onset for both dominant and subclonal KMT2A-MLLT3 + FLT3 N676K leukemias as compared to KMT2A-MLLT3 + Empty-GFP (both P < 0.0001. Mantel-Cox log-rank test). c Evolution of FLT3 N676K -GFP + cells within the mCherry + leukemic population between primary (1°) spleen (SPL) and secondary (2°) BM showed a significant expansion of KMT2A-MLLT3-mCherry + FLT3 N676K -GFP cells (n = 24, P < 0.0001. Paired ttest) but not of KMT2A-MLLT3-mCherry + Empty-GFP cells (n = 21, P = 0.1468. Paired t-test). d Cell cycle analysis of primary leukemia cells showed a higher cell cycle rate for KMT2A-MLLT3-mCherry cells harboring FLT3 N676K -GFP (n = 7) as compared to KMT2A-MLLT3 + Empty-GFP (n = 7). Error bars are s.d. **P ≤ 0.01, ****P ≤ 0.0001; ns, not significant activating mutations could affect the growth or survival of other leukemia cells. We hypothesized that a low initial number of cells co-expressing an activating mutation and KMT2A-MLLT3 together with a several fold higher number of cells expressing only KMT2A-MLLT3 would allow for the formation of distinct subclones and performed three additional experiments accordingly
(1:28, 1:41, and 1:156 for KMT2A-MLLT3 + FLT3 N676K :KMT2A-MLLT3 alone, respectively) ( Supplementary Fig. 5a ). We focused our analyses on FLT3 N676K , the most common FLT3 mutation in our series of infant and childhood KMT2A-R leukemia 4 . Combined analysis of the transplantations showed that despite the low number of cells that co-expressed KMT2A-MLLT3 and (6.6) ) in addition to a normal chromosome 6 in 8/38 (21%) metaphases. Together with the observed MAF this suggests that all disomic cells were heterozygous for Kras G12D mutation and all cells with three copies of chromosomes 6 had duplicated the mutated allele. f Fish plot showing a dominant Ptpn11 S506W which was preserved in size; MAF 0.39 (SJ016332) ->0.41 (SJ046294). g Kaplan-Meier survival curve for secondary KMT2A-MLLT3 recipients, showing accelerated disease for mice that harbored Braf V637E , Kras G12D , and Ptpn11 S506W (n = 3) as compared to those lacking an identified de novo mutation (n = 25; P = 0.0083. Mantel-Cox log-rank test). h, i Fish plots of secondary KMT2A-MLLT3 + Empty-GFP recipients that gained de novo mutations in h Ptpn11 S506W and i Ptpn11 E69K (MAF 0.31 and 0.29, respectively). j Kaplan-Meier curves of mice transplanted with BM co-transduced with either KMT2A-MLLT3 + Ptpn11 S506W (n = 7) or KMT2A-MLLT3 + Empty-GFP (n = 6), showing accelerated disease on onset for KMT2A-MLLT3 + Ptpn11 S506W recipients (P = 0.0005. Mantel-Cox log-rank test). **P ≤ 0.01, ***P ≤ 0.001 FLT3 N676K at transplantation, these mice displayed accelerated AML onset (median latency 34 versus 50 days for KMT2A-MLLT3 alone, P < 0.0001. Mantel-Cox log-rank test) (Supplementary Fig. 5b-f) . Interestingly, the BM of KMT2A-MLLT3 + FLT3 N676K recipients were comprised of either (1) a dominant clone, >50% (17/24 mice), or (2) a subclone, <50% (7/24 mice) of KMT2A-MLLT3 + FLT3 N676K expressing cells, hereafter referred to as dominant clone and subclone, respectively (Fig. 2a) . Importantly, when recipients were divided based on the fraction of FLT3 N676K expressing leukemic cells, mice with subclonal FLT3 N676K still succumbed to disease at an earlier onset (dominant clone, 32 days, P < 0.0001; subclone, 37 days P < 0.0001. Mantel-Cox log-rank test) (Fig. 2b ). There was a weak but significant correlation between clone size and disease latency (r s = −0.586, P = 0.0026. Spearman´s rank correlation coefficient) ( Supplementary Fig. 5g ). Our data therefore suggest that subclonal activating mutations accelerate KMT2A-R leukemogenesis.
Clonal evolution of FLT3 N676K containing leukemic cells. We next investigated the evolution of cells co-expressing FLT3 N676K and KMT2A-MLLT3 in secondary sublethally irradiated recipients. Primary splenocytes were used for these experiments and the fraction of cells co-expressing FLT3 N676K and KMT2A-MLLT3 was significantly smaller in spleen as compared to BM with 13/24 mice having a dominant clone and 11/24 a subclone ( Supplementary Fig. 5h ). Disease latency in secondary recipients was reduced and a small difference in survival was observed; median 16 days for KMT2A-MLLT3 + FLT3 N676K and 21 days for KMT2A-MLLT3 alone, P = 0.0293 (Mantel-Cox log-rank test) ( Supplementary Fig. 5i) . Secondary recipients were then divided based on the fraction of FLT3 N676K containing cells in the spleens of primary recipients, showing that size had a modest effect on disease latency ( Supplementary Fig. 5j , k).
Clonal evolution of leukemia splenocytes from primary recipients in the BM of secondary recipients showed three distinct patterns. Most frequently, the KMT2A-MLLT3 + FLT3 N676K cells increased in size (21/24 mice) ( Fig. 2c and Supplementary Fig. 5l ). In concordance, FLT3 N676K expression induced a higher cell cycle rate (Fig. 2d) . However, mice receiving cells from primary recipients with a very small KMT2A-MLLT3 + FLT3 N676K clone (≤10.1%, 3/24 mice) displayed a diverse evolution where one subclone (1.1%) was maintained in size, one (0.5%) disappeared, and one decreased in size from 10.1% to 0.1 % ( Fig. 2c and Supplementary Fig. 5m , n). Thus, cells containing an activating mutation typically had a persistent selective advantage also in established disease. However, in a few recipients, these cells failed to outgrow leukemia cells containing KMT2A-MLLT3 alone (see below).
KMT2A-MLLT3 cells acquire de novo signaling mutations. The failure of FLT3 N676K containing cells to expand in a subset of secondary recipients suggested that the KMT2A-MLLT3 only cells could have acquired de novo mutations. We therefore sequenced 41 selected genes that were either tyrosine kinases, within the PI3K/RAS pathways, epigenetic regulators, or recurrently mutated in KMT2A-R leukemia (see Methods and Supplementary  Table 1 ) at a mean coverage of 3231 ± 1277 (s.d.) (Supplementary Data 1), in 62 primary (27 dominant and 7 subclonal KMT2A-MLLT3 and an activating mutation, and 28 KMT2A-MLLT3 alone) and 29 paired secondary recipients (derived from 15 dominant and 6 subclonal KMT2A-MLLT3 and an activating mutation, and 8 KMT2A-MLLT3 alone) (Supplementary Table 2) . Notably, our analyses identified acquired de novo mutations in RAS pathway genes in 4/62 primary-and in 6/29 paired secondary recipients, all of which occurred in genes known to be mutated in human KMT2A-R leukemia (Ptpn11, Cbl, Braf, Kras) and all but one mutation (Cbl A308T ) occurred at amino acid positions known to be activating ( Supplementary Fig. 6a -h and Supplementary Data 2) [21] [22] [23] [24] . In every case, as determined by RNA sequencing, the acquired mutation was expressed (Supplementary Data 2).
Only 1/34 (3%) of the primary KMT2A-MLLT3 recipients that co-expressed FLT3 ITD , FLT3 N676K , or NRAS G12D had acquired a de novo mutation (Cbl A308T ) ( Fig. 3a and Supplementary Data 2). Strikingly, Cbl A308T was detected in the mouse in which the frequency of KMT2A-MLLT3 + FLT3 N676K cells decreased in size in the secondary recipient. The Cbl A308T was subclonal in the primary (MAF 0.11), dominant in the secondary (MAF 0.37) and maintained in size in a tertiary recipient ( Fig. 3a and Supplementary Data 2). Thus, in the primary recipient, KMT2A-MLLT3 cells acquired a Cbl A308T that had a selective advantage over FLT3 N676K leukemia cells and gained clonal dominance in the secondary recipient. Cbl encodes a RING ubiquitin ligase that functions as a negative regulator of signaling pathways. The corresponding human residue of A308 (A310) is located in the highly conserved N-terminal SH2 domain within the tyrosine kinase-binding domain ( Fig. 3b and Supplementary  Fig. 6a , b), which mediates substrate specificity and is critical for substrate ubiquitination. Mutations occur over the whole region of CBL, with the RING domain being a hotspot; no A310 mutations have been reported in COSMIC 25 ( Supplementary  Fig. 6b ). The CBL G306E results in a complete loss of its ability to bind SYK and FLT3 26, 27 . Given the close proximity of A310 and G306 ( Fig. 3b and Supplementary Fig. 6i ), Cbl A308T likely also interferes with binding and subsequent ubiquitination of target substrates, such as Syk and Flt3. Mutations in CBL cause factor independent growth of the IL3 dependent cell line Ba/F3 when overexpressed with certain receptor kinases such as FLT3 28 . Using the same approach [28] [29] [30] , we functionally demonstrated that expression of Cbl A308T resulted in a significantly higher cell proliferation as compared to Cbl WT , supporting that the A308T mutation interferes with the ability of Cbl to negatively regulate intracellular signaling ( Supplementary Fig. 7a ). Taken together, when the constitutively active mutation is present as a subclone, there is a selective benefit of acquiring activating mutations in leukemia cells lacking such a mutation.
Acquired mutations were more common in mice lacking a constitutively expressed activating mutation, with 3/28 (11%) primary and 5/8 secondary KMT2A-MLLT3 recipients containing such mutations. Mutations in Braf V637E , Kras G12D , and Ptpn11 S506W were identified in three primary and in their corresponding secondary recipient ( Fig. 3c-f and Supplementary Data 2). In secondary transplantations, the three KMT2A-MLLT3 leukemias with Braf V637E , Kras G12D , or Ptpn11 S506W were associated with accelerated disease (Fig. 3g) . Further, a Ptpn11 S506W and a Ptpn11 E69K were identified in two additional secondary recipients, with no evidence of the mutant allele in their corresponding primary recipient (Fig. 3h, i and Supplementary Data 2). Using directed amplicon sequencing, additional secondary KMT2A-MLLT3 leukemias were screened for Braf V637E (n = 14), Cbl A308T (n = 14), Kras G12D (n = 15), Ptpn11 E69K (n = 15), and Ptpn11 S506W (n = 13), but no mutations were identified. The Braf V637E and Kras G12D (human orthologues BRAF V600E and KRAS G12D ) are well-described mutations that cause constitutively active signaling in humans and mice ( Supplementary Fig. 6c-f) 21, 22 . The only recurrently mutated gene was the proto-oncogene tyrosine phosphatase Ptpn11 (encoding Shp-2), acquired in three separate leukemias, Ptpn11 E69K (n = 1) and Ptpn11 S506W (n = 2). These mutations are located in the C-terminal SH2 and protein tyrosine Fig. 6g, h ). SHP-2 positively regulate RAS signaling 31 and mutations are seen in KMT2A-R acute leukemia of all ontogenies 4, 7 . Mutations at E69 and S502 are known to increase SHP-2 phosphatase activity 23, 24 , suggesting that also the mouse mutations would have similar effect. Coexpression of Ptpn11 S506W and KMT2A-MLLT3 accelerated AML onset compared to control mice (median latency 27 vs. 44 days, P = 0.0005. Mantel-Cox log-rank test) with a majority of KMT2A-MLLT3 cells containing Ptpn11 S506W (Fig. 3j and Supplementary  Fig. 7b-f) . Thus, Ptpn11 S506W is a cooperating mutation in KMT2A-R leukemogenesis. The availability of a paired secondary leukemia allowed us to study the evolution of the acquired mutations. The Braf V637E was subclonal at leukemia onset (MAF 0.20) and increased in size in the secondary recipient (MAF 0.30) (Fig. 3c and Supplementary  Data 2) . Similarly, Kras G12D was subclonal (MAF 0.11) at leukemia manifestation and gained clonal dominance in the Data 3, 4) . Principal component analysis of purified normal hematopoietic subpopulations showed distinct clusters based on maturation stage and that the leukemias mostly resembled normal granulocyte-macrophage progenitors (GMPs) ( Supplementary  Fig. 8a ) 19 . All leukemias had high expression of Hoxa9, Hoxa10, and Meis1, known KMT2A-R target genes, as compared to GMP cells ( Supplementary Fig. 8b ) 19 . Gene set enrichment analysis (GSEA) 37 revealed enrichment of signatures from pediatric KMT2A-R AML ( Supplementary Fig. 8c and Supplementary Data 5), supporting that mouse leukemias activate similar pathways as human KMT2A-R leukemia and is a representative model of this disease.
Despite a shared KMT2A-R leukemic signature, mutant FLT3 and NRAS expression also induced distinct gene expression profiles (GEPs) (Fig. 4a, Supplementary Fig. 8d-f and Supplementary Data 6). To link the GEPs induced by activating mutations in our mouse model to that seen in human disease, GSEA was performed using a gene signature associated with infants harboring KMT2A-AFF1 and an activating mutation 4 , which demonstrated enrichment of this signature in mice with activating mutations (Fig. 4b) . This indicates that the transcriptional changes induced by activating mutations in human disease are preserved in the mouse. Notably, identified de novo mutations influenced the GEP for samples with mutations in the dominant leukemia clone, i.e., Kras and Ptpn11 (MAF 0.39-0.59), now clustering closely to those with a constitutively expressed mutation; this was not seen for mutations with MAF ≤ 0.30 (Fig. 4c) .
Although FLT3 ITD , FLT3 N676K , and NRAS G12D each had distinct GEPs, they induced similar biological processes at the gene and protein level, including a distinct enrichment of MYC signatures ( Fig. 4d and Supplementary Data 7-14) . The MYC regulatory network enhances embryonic stem cell (ESC) programs, but is separate from the pluripotency network 38 . Indeed, the signature evoked by activating mutations was specific to the MYC module 38 (Fig. 4e, Supplementary Fig. 8g , h, and Supplementary Data 15-23). In line with this, ribosomal and translational signatures, MYC influenced processes 39 , were enriched at the RNA and protein level ( Supplementary Fig. 8i -k and Supplementary Data 24-26). The MYC signature likely reflect a worse prognosis 38, 40 , in line with the rapid disease progression for these mice 34, 38, 41 ( Supplementary Fig. 9a and Supplementary Data 16-19 ). Myc is a direct target gene of MYB 42 , a transcription factor known to be a key regulator of hematopoietic stem and progenitor cells and to be an important mediator in KMT2A-R leukemia 34, 35 . Further, Myb is associated with a leukemia maintenance signature in KMT2A-R leukemia models 35 and this signature was enriched in leukemias with an activating mutation at the gene and protein level (Supplementary Fig. 9b, c and Supplementary Data 16-23 ). However, Myb was not part of the leading-edge genes, but was uniformly expressed in all leukemias, including those expressing KMT2A-MLLT3 alone Supplementary  Fig. 9b-d, and Supplementary Data 17-19) . The Myc and Myb signatures mainly associated with committed progenitors as opposed to regenerative hematopoietic populations (Supplementary Fig. 9e, f) . Enrichment of the Myc and Myb signatures was also observed in mouse leukemias with de novo Kras/Ptpn11 mutations (MAF 0.39-0.59) and in primary infant KMT2A-AFF1 ALL harboring activating mutations 4 (Fig. 4f, Supplementary  Fig. 9g -j, and Supplementary Data 27, 28).
To gain further insight into the transcriptional effect on downstream MEK/ERK signaling in leukemias with activating mutations, we selectively investigated if expression of FLT3 ITD , FLT3 N676K , and NRAS G12D caused increased expression of known transcriptional output genes and negative feedback regulators of MEK/ERK signaling 43 . Indeed, enrichment of these genes were particularly strong in KMT2A-MLLT3 mouse leukemia with NRAS G12D and in infant KMT2A-AFF1 ALL patients harboring activating mutations ( Supplementary Fig. 9k and Supplementary Data 19, 28) 4 . However, enrichment was also seen for KMT2A-MLLT3 mouse leukemia with FLT3 N676K or Kras/Ptpn11 mutations (MAF 0.39-0.59) ( Supplementary Fig. 9k and Supplementary Data 18, 27) . This implicates an increased transcriptional activity of the MEK/ERK signaling pathway including negative feedback regulators in leukemia with signaling mutations, in particular those with FLT3 N676K and NRAS G12D , and that the mutant cells are insensitive to negative feedback control. The same enrichment was not observed for FLT3 ITD leukemias ( Supplementary Fig. 9k and Supplementary Data 17) .
KMT2A-MLLT3 recipients lacking an activating mutation had increased expression of genes involved in signal transduction (Fig. 4g ) when compared to all leukemias that co-expressed KMT2A-MLLT3 and an activating mutation ( Supplementary  Fig. 8f ). Consistent with this, GSEA revealed enrichment of intracellular signaling pathways including different MAPK pathways, both at gene-and protein level (Fig. 4h, Supplementary  Fig. 8i-k and Supplementary Data 7-14, 24-26 ). This suggests that KMT2A-MLLT3 itself may cause sustained transcription and subsequent translation of genes involved in intracellular signaling.
MIF promotes survival of KMT2A-MLLT3 leukemia cells. Mice expressing subclonal FLT3 N676K succumb earlier to disease than those lacking such a mutation (Fig. 2b) , raising the possibility that cells with an activating mutation, whether present at high or low MAF, provide factors that positively influence the growth or survival of leukemia cells. We therefore investigated the expression of 137 genes encoding cytokines or growth factors (Supplementary Data 29), revealing a differential expression of several of these genes between leukemia cells with or without an activating mutation (Supplementary Fig. 10a ). One cytokine commonly upregulated in KMT2A-MLLT3 leukemias co-expressing an activating mutation (FLT3 ITD , FLT3 N676K , or NRAS G12D ) as compared to those induced by KMT2A-MLLT3 alone, and normal healthy hematopoietic subpopulations, was the macrophage migration inhibitory factor (Mif), a lymphokine that stimulate pro-inflammatory processes ( Fig. 5a and Supplementary  Fig. 10b ). Proteomic analyses confirmed a higher expression of MIF in a majority of KMT2A-MLLT3 leukemias with an activating mutation (Fig. 5b and Supplementary Fig. 11a ). To establish the role of MIF in human KMT2A-R leukemia, we determined its expression in infant KMT2A-AFF1-rearranged ALL, showing that MIF was significantly higher expressed in patients with activating mutations (Fig. 5c) 4 . We therefore evaluated whether MIF alone was sufficient to promote growth and survival of murine KMT2A-MLLT3 cells, which are dependent on IL3 for their survival ex vivo 10 . We found that MIF positively influenced survival of KMT2A-MLLT3 leukemia cells when cultured without IL3 (Fig. 5d) . Given that MIF influenced the survival of KMT2A-MLLT3 leukemia cells ex vivo (Fig. 5d) , we next assessed whether MIF stimulation maintained leukemia-initiating cells (LICs) ex vivo using a transplantation assay. For this purpose, 5000 serially transplanted and LIC-enriched KMT2A-MLLT3 c-Kit + leukemia cells 44 were cultured ex vivo for 3 days with or without MIF before transplantation into sublethally irradiated recipients (Supplementary Fig. 11b ). Mice transplanted with MIF treated cells had significantly shorter disease latency as compared to no cytokine control mice (22.5 days versus 28 days, P ≤ 0.0001. Mantel-Cox log-rank test), suggesting that MIF promotes survival of LICs (Fig. 5e, f and Supplementary  Fig. 11d-f) .
Discussion
We lack a full understanding of the biological processes controlling and shaping the selection of evolving leukemia clones. Mouse models have proven powerful tools to uncover genetic interactions, and the spontaneous acquisition of mutations in genes that in humans promote leukemogenesis identified herein, highlights their remarkable capacity to recapitulate human disease. Our study demonstrates that an activating mutation present only in a small proportion of KMT2A-MLLT3 leukemia cells can Table 4 ). b Relative MIF protein abundance in mouse KMT2A-MLLT3 leukemic cells with or without FLT3 ITD , FLT3 N676K , or NRAS G12D as determined by quantitative mass spectrometry. c MIF expression in infant KMT2A-AFF1 ALL patients with activating mutations (dominant or subclonal) to those lacking such mutations 4 . d Number of viable KMT2A-MLLT3 leukemia cells when cultured with increasing concentrations of MIF after 6 days of ex vivo culture without IL3 (n = 3). e Kaplan-Meier survival curve for recipient mice transplanted with serially propagated dsRed + KMT2A-MLLT3 cells 44 cultured ex vivo for 3 days with or without 500 ng/ml MIF. f Flow cytometric analysis on bone marrow (BM) from moribund mice revealed a majority of leukemia (dsRed + ) cells in all mice. * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001, **** P ≤ 0.0001; ns, not significant influence the rate of leukemogenesis and shorten time to leukemia onset. These data support a model whereby subclonal activating mutations are not bystanders, but influence leukemogenesis. This is the first time, to the best of our knowledge, that the functional importance of a defined leukemia subclone has been studied in the mouse. In addition, our data show that FLT3 N676K , the most frequent FLT3 mutation identified in our previous analysis of the mutational landscape of infant and childhood KMT2A-R leukemia 4 , is a cooperating lesion in this disease.
The observation that subclonal activating mutations accelerate disease onset in the mouse, is consistent with our previous data showing that activating mutations, irrespective of their MAFs, associated with an average younger age at diagnosis in infants with KMT2A-AFF1 ALL 4 . Typically, subclonal FLT3 N676K cells had a continued proliferative advantage upon secondary transplantation. However, sometimes these cells failed to expand, and we identified spontaneous de novo signaling mutations in Ptpn11 E69/S506 , Braf V637E , Cbl A308T , and Kras G12D , in cells bearing only KMT2A-MLLT3, thereby shifting clonal balance. Notably, further clonal evolution at the Kras locus was evident upon secondary transplantation, consistent with duplication of the mutated allele and a strong selective advantage of additional Kras G12D45 (Fig. 3e) . In human disease, data from large scale sequencing efforts have shown that patients may have more than one signaling mutation often present at different MAFs indicative of multiple leukemia clones 4, 7 . Our data are consistent with different activating mutations providing different fitness to evolving leukemia cells, thus influencing their selection potential. The lack of identified spontaneous mutations in cells co-expressing KMT2A-MLLT3 and FLT3 ITD , FLT3 N676K , or NRAS G12D suggest that in the presence of a strong signaling mutation, the selective pressure for additional mutations within the pathway is not as prominent, at least not when the mutation is retrovirally overexpressed.
The fact that a subclonal activating mutation reduce leukemia latency raises the possibility that they secrete stimulating factors that influence other leukemia cells, as has been shown in solid tumor models with activating mutations [46] [47] [48] [49] [50] [51] . MIF, a proinflammatory cytokine, was highly expressed in KMT2A-MLLT3 leukemia with activating mutations both in mice and in primary infant ALL patients (Fig. 5c ). MIF treatment ex vivo supported the survival of mouse KMT2A-MLLT3 LICs. Thus, MIF is likely one of many factors that mediate pro-leukemic signals in vivo. MIF can inactivate p53 and thereby suppress apoptosis 52, 53 and can also communicate with stromal cells, as recently described for primary AML cells, resulting in increased tumor cell survival 54 . In addition, knockout of Mif delayed development of chronic lymphocytic leukemia (CLL) in mice and, similar to our data, MIF extended survival of CLL cells in vitro 55 .
It is well described that genetic aberrations shape GEPs in leukemia. Mutations in NRAS G12D , FLT3 ITD and FLT3 N676K further enforced Myc-and Myb-driven signatures previously associated with KMT2A-R leukemia 34, 35, 38 . MYC levels are influenced by RAS and kinase signaling 39, 56 , in line with activating mutations extending this transcriptional program. Signaling mutations affecting the ERK pathway, in mice as well as in infant ALL, resulted in increased transcriptional output of the pathway including negative feedback regulators, suggesting that mutated cells are insusceptible to negative regulation (Supplementary Fig. 9k) 43, 45 . Interestingly, KMT2A-MLLT3 leukemias lacking a constitutively expressed signaling mutation, sustain or upregulate intracellular signaling pathways, such as RAC1 and MAPK, potentially as a contributing oncogenic event. Elevated RAC1 protein levels confer anti-apoptotic capacity in KMT2A-MLLT3 leukemia [57] [58] [59] .
Taken together, these data provide a unique look into the mechanisms by which activating mutations affect leukemogenesis, also when present as a subclone. The data suggest that subclonal activating mutations, here demonstrated by FLT3 N676K , can influence leukemogenesis, possibly by providing pro-leukemic factors. In the absence of a constitutively active mutation, KMT2A-R leukemia cells may acquire spontaneous activating mutations, consistent with the importance of kinase/ PI3K/RAS pathways as a cooperating event in this disease. The acquired mutations typically conferred cells with a competitive advantage, altered clonal fitness, and favored clonal outgrowth. Our results provide insight into the mechanisms by which signaling mutations promote leukemogenesis and it will be important to determine whether interfering with intracellular signal transduction in human KMT2A-R leukemia, even in the absence of an activating mutation, may be a fruitful therapeutic approach 7, 60 .
Methods
Vectors and virus production. All vectors were based on the Murine Stem Cell Virus (MSCV) backbone and the following vectors were used: MSCV-KMT2A-MLLT3-IRES-mCherry, MSCV-FLT3 N676K -IRES-GFP, MSCV-FLT3 ITD -IRES-GFP, MSCV-FLT3 D835Y -IRES-GFP, MSCV-FLT3 WT -IRES-GFP, MSCV-NRAS G12D -IRES-eGFP, and MSCV-NRAS WT -IRES-eGFP. ORF cDNA clones for Cbl (NM_007619) and Ptpn11 (NM_011202) subcloned into MSCV-eGFP were purchased from Genscript (Piscataway, NJ, USA). Site-directed mutagenesis to obtain Cbl A308T and Ptpn11 S506W was performed using the QuikChange II XL Site Directed Mutagenesis Kit (Agilent Technologies, Santa Clara, CA, USA) according to the manufacturer´s instructions using the following primers; Cbl A308T -F 5′-TGTTCCCATCGGTAGTAACATACCCAATAGCCCACT-3′, Cbl A308T -R 5′-AGTGGGCTATTGGGTATGTTACTACCGATGGGAACA-3′, Ptpn11 S506W -F 5′-ACCATCCCCCACCTCTGGGACCGC-3′ and Ptpn11 S506W -R 5′-GCGGTCCCA-GAGGTGGGGGATGGT-3′; mutations were verified by Sanger sequencing. Empty vectors lacking the transgenes were used as controls. Retroviral supernatants were produced according to standard protocols using transient transfection of HEK 293T cells and viral containing medium was harvested 36 h later and stored at −80°C .
Retroviral transduction.
Whole bone marrow (BM) cells were harvested from 8-12 weeks old C57Bl/6xB6SJL mice and CD117 + cells were enriched by magnetic activated cell sorting (Miltenyi Biotech, Bergisch Gladbach, Germany). Cells were pre-stimulated for 48 h in StemSpan™ SFEM (Stemcell Technologies, Grenoble, France) supplemented with 100 units/mL Penicillin and 100 g/ml Streptomycin (Thermo Scientific, South Logan, UT, USA), 50 ng/ml mSCF, 50 ng/ml hIL6, 50 ng/ ml hTPO, and 20 ng/ml mIL3 (all cytokines were purchased from Peprotech, Rocky Hill, NJ, USA). Retroviral co-transduction was performed by loading a defined mixture of retroviral supernatant on Retronectin (Takara, Otsu, Japan) precoated wells by centrifugation for 60 min at 1000×g in 4°C. Cells were then added, spun down at 320×g for 5 min and incubated at 37°C for 15-18 h before bone marrow transplantation. A small aliquot of cells was saved in culture to determine the frequency of single and co-transduced cells by flow cytometry 48 h post transduction. IL3-dependent Ba/F3 cells (DSMZ, Braunschweig, Germany) were transduced in standard culture medium.
In vivo bone marrow transplantation models. C57Bl/6NTac, C57Bl/6xB6SJL and B6SJL mice were used throughout the experiments. C57Bl/6xB6SJL and B6SJL mice were bred in-house and sex and age matched C57Bl/6NTac were purchased from Taconic (Ejby, Denmark). For primary bone marrow transplantations, 8-12 weeks old and age-matched female C57Bl/6NTac mice were lethally irradiated with 900 cGy 18-20 h prior to transplantation and subsequently transplanted with 1 × 10 6 unfractionated co-transduced C57Bl/6xB6SJL BM cells. For all primary transplantations, 400,000 freshly isolated B6SJL whole BM cells were given as support, and recipient mice were given Ciprofloxacin (KRKA, Stockholm, Sweden) for 2 weeks post-irradiation in the drinking water. For secondary transplantations, 8-12 weeks old and age matched female C57Bl/6NTac mice were sublethally irradiated with 450 cGy 6 h prior to transplantation and were subsequently transplanted with 1 × 10 6 whole spleen cells from primary recipients. For all mice, when moribund, a PB sample was taken from vena saphena, and mice were then sacrificed by cervical dislocation. Upon sacrifice; one femur and a piece of the liver and spleen were saved for pathological evaluation. Remaining bones and spleen were made into single-cell suspension by manual trituration and BM and spleen cells were viably frozen. In addition, 1 × 10 6 BM cells were lysed in RLT buffer (Qiagen, Hilden, Germany) supplemented with 1% β-mercaptoethanol (SigmaAldrich, St. Louis, MO, USA) and stored in −80°C before further DNA/RNA extraction. Complete blood cell count was performed on PB using Micros 60 CS Table 1 ) was constructed based on two unbiased sequencing efforts of infant, childhood and adult KMT2A-R leukemia 4, 7 , and selected genes were either recurrently mutated in its respective study or part of a PI3K/RAS/kinase-or epigenetic pathway. An additional nine genes were manually added (Supplementary Table 1 ). PCR amplicon library preparation was performed using Illumina TruSeq Custom Amplicon Low Input according to manufacturer´s instructions (v03). In short, 20 ng of mouse genomic DNA was hybridized with the custom oligo pool, bound oligos were extended and ligated after which the libraries were amplified. Library concentrations were determined by the Qubit Fluorometer (Life Technologies), libraries were pooled and 2 × 150 bp paired-end sequencing was performed using the Illumina NextSeq 500 (Illumina). Paired-end reads from the targeted amplicon deep sequencing were aligned to the mouse genome mm9 on BaseSpace (Illumina) using a banded Smith-Waterman algorithm and Bedtools was used to calculate coverage. Mpileup files were created using SAMtools (1.3.1) 62 and variant calling was performed using VarScan (2.4.1) 63 . Putative mutations were filtered based on quality and resultant variants were manually reviewed using Bambino 64 . For calculations of mutant allele frequencies, the number of reads required for the mutant allele was ≥100, otherwise data from the PCR amplicon validation was used. Fish plots depicting clonal evolution between primary and secondary recipients were based on mutant allele frequencies for single nucleotide variants as determined by the targeted amplicon sequencing (Supplementary Data 2) and frequencies of cells displaying aberrant interphase FISH analysis signals (Supplementary Table 3 ).
Validation of somatic mutations. Validation of each mutation was performed in matched primary, secondary recipient, and constitutional DNA, using PCR amplicon deep sequencing. Primers were designed using Primer-BLAST (sequences available upon request). PCR was performed using Platinum Taq DNA Polymerase kit (Life Technologies) according to the manufacturer's instructions and products were analyzed using gel electrophoresis. PCR amplicons were purified using AMPure XP beads (Beckman Coulter Inc., Brea, CA) and prepared for sequencing using the Nextera XT DNA Sample Preparation Kit and Index Kit (Illumina). 2 × 150 bp paired-end sequencing was performed using the Illumina NextSeq 500 (Illumina) and paired-end reads were aligned to mm9 using BWA (0.7.12).
Fluorescence in situ hybridization (FISH). FISH was performed according to standard methods on cultured BM cells from the primary (SJ016338) and secondary (SJ046295) recipients with acquired Kras G12D , utilizing BACs BMQ-415F20, BMQ-422H6 and BMQ-189B18 (Source BioScience, Nottingham, UK), overlapping the Kras locus, and a whole chromosome paint probe for chromosome 6 (MetaSystems Probes GmbH, Altlussheim, Germany). A minimum of 100 interphase and 10 metaphase cells were scored for each sample. g/ml Streptomycin (Thermo Scientific) supplemented with 10 ng/ml mIL3 (Peprotech). For cytokine independency assay, cells were washed three times in PBS + 2% FBS and seeded in triplicates at a density of 0.5 × 10 6 cells/ml in 1 ml in 12-well plates. Cells were counted continuously using CountBright beads (Life Technologies) on a FACS Fortessa (BD) for up to 19 days. Ba/F3 cells treated with 10 ng/ml mIL3 was included as a positive and Ba/F3 without mIL3 was used as a negative control. Cells were split when cell numbers reached 2 × 10 6 cells/ml to 0.2 million/ml.
DNA/RNA extraction and RNA sequencing. RNA and DNA were extracted using AllPrep DNA/RNA Mini Kit (Qiagen) according to the manufacturer's instructions. The DNA quantity and quality was assessed by the NanoDrop 1000 Spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA) and the Qubit Fluorometer (Life Technologies, Paisley, UK), respectively. The RNA quantity and quality was assessed by the NanoDrop 1000 Spectrophotometer (Thermo Fisher Scientific) and the Agilent 2100 Bioanalyzer (Agilent Technologies), respectively. Selection of poly(A) mRNA and subsequent cDNA synthesis was performed using the Illumina TruSeq RNA sample preparation kit (Illumina, San Diego, CA, USA) according to the manufacturer's instructions, but with a modified RNA fragmentation step lowering the incubation at 94°C from 8 min to 10 s. Quality and size of the library were analyzed using the Agilent 2100 Bioanalyzer (Agilent Technologies) and 2 × 80 bp paired-end sequencing was performed on Illumina NextSeq 500 (Illumina).
Analysis of RNA sequencing data. Paired-end reads from RNA sequencing were aligned to the mouse genome mm9 using BWA (0.5.10) aligner and a bam file was constructed from which coverage was calculated using an in-house pipeline. Transcript expression levels were estimated as fragments per kilobase of transcript per million mapped fragments (FPKM) and gene FPKM was calculated using Cuffdiff2 65 and log 2 transformed. A FPKM cutoff of ≥0.5 was used to define "expressed" genes and genes not expressed in at least one sample were excluded. For the expression matrix with normal hematopoietic populations 36 data was quantile-normalized. Visualization and statistical analysis was performed using Qlucore Omics Explorer 3.1 (Qlucore, Lund, Sweden). GSEA was performed using GSEA v2.2.0 37 with pre-ranked gene lists and gene ontology was performed using DAVID 66 .
Sample preparation for proteome analysis. FACS was used to isolate GFP + mCherry + leukemic BM cells from three KMT2A-MLLT3 + NRAS G12D mice (SJ017001, SJ017002 and SJ017003), four KMT2A-MLLT3 + FLT3 ITD mice (SJ017005, SJ017006, SJ017007 and SJ017008), four KMT2A-MLLT3 + FLT3 N676K mice (SJ017009, SJ017010, SJ017011 and SJ017012) as well as mCherry + leukemic BM cells from four KMT2A-MLLT3 + Empty-GFP mice (SJ018148, SJ018150, SJ018151 and SJ018152). Cells were stored as cell pellets in −80°C. Cell pellets corresponding to 1 × 10 6 FACS-sorted cells were lysed with 0.1% RapiGest (Waters, Milford, MA, USA) in 55 µl 200 mM HEPES (pH 8), heated at 90°C for 5 min, followed by sonication for 20 min and removal of cell debris by centrifugation. Cysteine disulfide bonds were reduced with 5 mM DTT for 30 min at 56°C, alkylated with 10 mM iodoacetamide for 30 min at room temperature in the dark, and proteins were digested with Mass Spectrometry Grade Lysyl Endopeptidase (Wako, Osaka, Japan) at enzyme:protein ratio 1:50, at 37°C overnight. Peptides were differentially labeled with Tandem Mass Tag isobaric labeling (TMT 6-plex, Thermo Scientific) according to the manufacturer's instructions with slight modifications. Briefly, 0.8 mg TMT reagents were dissolved in 40 µl acetonitrile and 5 µl was added to each sample. After 30 min (shaking), another 5 µl TMT reagent was added and samples were shaken for 30 min. The reaction was quenched by adding 8 µl of 5% hydroxylamine and samples were incubated at RT for 15 min. RapiGest was then precipitated by addition of 10 µl 10% trifluoroacetic acid and incubation at 37°C for 45 min. Following centrifugation, supernatants were collected and samples were desalted with SepPak C 18 cartridges (Waters) by washing the columns with acetonitrile, conditioning and loading samples in 0.1% (v/v) trifluoroacetic acid, washing with 0.1% formic acid and eluting peptides with 80% (v/ v) acetonitrile/0.1% (v/v) formic acid. For the control mix, four KMT2A-MLLT3 + Empty-GFP samples (all labeled with TMT 126) were mixed at this stage and split into three equal volumes. Samples were dried by vacuum centrifugation, reconstituted in IPG rehydration buffer and fractionated according to manufacturer's instructions using pH 3-10 IPG strips and 3100 OFFGEL fractionator (Agilent Technologies). The 12 resolved fractions were acidified and desalted with C 18 Ultra-Micro Spin Columns (Harvard Apparatus, Holliston, MA, USA). Peptide samples were dried by vacuum centrifugation and stored at −20°C until further use. Samples were reconstituted in 4% acetonitrile/0.1% formic acid prior to MS analysis.
Proteome analysis. MS analyses were carried out on the Orbitrap Fusion Tribrid MS system (Thermo Scientific) equipped with a Proxeon Easy-nLC 1000 (Thermo Fisher). Injected peptides were trapped on an Acclaim PepMap C18 column (3 µm particle size, 75 µm inner diameter × 20 mm length, nanoViper fitting), followed by gradient elution of peptides on an Acclaim PepMap C18 100 Å column (3 µm particle size, 75 µm inner diameter × 150 mm length, nanoViper fitting). The mobile phases for LC separation were 0.1% (v/v) formic acid in LC-MS grade water (solvent A) and 0.1% (v/v) formic acid in acetonitrile (solvent B). Peptides were loaded with a constant flow of solvent A at 9 μl/min onto the trapping column followed by peptide elution via the analytical column at a constant flow of 600 nl/ min. During the elution step, the percentage of solvent B increased in a linear fashion from 5% to 10% in 2 min, then to 25% in 85 min and finally to 60% in 20 min. The peptides were introduced into the mass spectrometer via a Stainless Steel Nano-bore emitter 150 µm OD × 30 µm ID; 40 mm length (Thermo Fisher Scientific) and a spray voltage of 2.0 kV was applied. The capillary temperature was set at 275°C.
Data acquisition was carried out using a data-dependent SPS-MS3 method with cycle time of 3 s. The master scan was performed in the Orbitrap in the range of 380-1580 m/z at a resolution of 120,000 FWHM. The filling time was set at maximum of 50 ms with limitation of 4 × 10 5 ions. Ion trap CID-MS2 was acquired using parallel mode, filling time 50 ms with limitation of 1.5 × 10 4 ions, a precursor ion isolation width of 0.7 m/z and resolution of 30,000 FWHM. Normalized collision energy was set to 35%. Only multiply charged (2+ to 5+) precursor ions were selected for MS2. The dynamic exclusion list was set to 30 s and relative mass window of 5 ppm. Precursor selection range for MS3 was set to m/z range 400-1200 in MS2. Orbitrap HCD-MS3 scans were acquired in parallel mode with synchronous precursor selection (ten precursors), normalized collision energy of 55%, filling time 120 ms with limitation of 1 × 10 5 ions and a resolution of 15,000 FWHM in a range of 100-500 m/z.
Proteome data analysis. MS raw data were processed with Proteome Discoverer (version 2.1, Thermo Scientific). Enzyme was set to LysC and a maximum of two missed cleavages were allowed. TMT-K and TMT N-term were set as static modifications. Data were annotated using SEQUEST search engine against the Uniprot mouse database (downloaded 2016.05.29) containing 79,920 proteins to which 197 frequently observed contaminants had been added, as well as the trans and reporter genes used in this study. Maximal allowed precursor mass tolerance was set to 10 ppm. 6756 proteins were identified of which 5941 fulfilled an FDR < 0.05. Of identified proteins, 94.9% could be linked to their corresponding mRNA in the RNAseq data of expressed genes (6411 out of 6756).
Statistical analysis was performed using the Limma package in R/ Bioconductor 67 . After fitting a linear model to the data, an empirical Bayes moderated t-test was used for the protein ratios. P-values were adjusted for multiple testing with Benjamini and Hochberg's method. To match proteomic and transcriptomic signatures, average log2 protein ratios and average mRNA ratios (as compared to KMT2A-MLLT3 + Empty-GFP) were combined for matching gene symbols and 2D enrichment was performed using Perseus (v1.5.5.3) 68 with an Benjamini-Hochberg FDR of 0.02.
MIF ex vivo treatment assays. For the cytokine assay, established mouse KMT2A-MLLT3 + Empty-GFP leukemic cells were washed once in cold PBS (GE Healthcare Life Sciences), resuspended in C10 medium supplemented with 25 ng/ ml mSCF (Peprotech) and plated in 100 µl at a density of 50,000 cells per well in a 96-well U-bottom plate and 5 µl recombinant human MIF (Peprotech) was added at a final concentration of 100 or 500 ng/ml, and PBS (GE Healthcare Life Sciences) was used as control. Cells were counted on day 6 after seeding using CountBright beads (Life Technologies, Eugene, OR, USA) on a FACS Fortessa (BD). Data analysis was performed using the FlowJo software (FlowJo, LLC).
For the ex vivo transplantation assay, serially propagated dsRed + KMT2A-MLLT3 leukemia cells 44 were used 69 . Briefly, 5000 freshly isolated CD117 + quaternary transplant leukemia cells were treated ex vivo with or without 500 ng/ ml MIF (Peprotech) in StemSpan™ SFEM (Stemcell Technologies) for 3 days before transplantation into sublethally irradiated (600 cGy) recipients. Blood sampling was performed 3 weeks post transplantation and at disease manifestation, BM cells from femurs and tibias were collected, and the percentage of dsRed + leukemia cells were determined using flow cytometry.
Statistical analysis. Differences between groups were assessed by unpaired or paired (when noted) Students t-test. Correlation was assessed using Spearman´s rank correlation coefficient. Statistical analysis of survival curves was performed using Mantel-Cox log-rank test. All graphs show mean with all individual data points. All analyses were performed with Prism software version 6.0 (GraphPad software).
Code Availability. GSE106714 and PXD008213. Referenced accession codes: SRP100343. Protein Data Bank: 2Y1M, 2Y1N, 3BUW, 3BUO, and 4A4B.
Data availability. RNA sequencing data have been deposited under the accession number GSE106714 in the Gene Expression Omnibus (GEO). Mass spectrometry proteome data have been deposited with the identifier PXD008213 to the ProteomeXchange Consortium via the Proteomics Identifications Database (PRIDE) partner repository 70 . All other relevant data are available from the corresponding author upon request. 
